A review of Dengvaxia®: development to deployment

Stephen J Thomas, In-Kyu Yoon, Stephen J Thomas, In-Kyu Yoon

Abstract

Dengue is the world's most prevalent and important arboviral disease. More than 50% of the world's population lives at daily risk of infection and it is estimated more than 95 million people a year seek medical care following infection. Severe disease can manifest as plasma leakage and potential for clinically significant hemorrhage, shock, and death. Treatment is supportive and there is currently no licensed anti-dengue virus prophylactic or therapeutic compound. A single dengue vaccine, Sanofi Pasteur's Dengvaxia®, has been licensed in 20 countries but uptake has been poor. A safety signal in dengue seronegative vaccine recipients stimulated an international re-look at the vaccine performance profile, new World Health Organization recommendations for use, and controversy in the Philippines involving the government, regulatory agencies, Sanofi Pasteur, clinicians responsible for testing and administering the vaccine, and the parents of vaccinated children. In this review, we provide an overview of Dengvaxia's® development and discuss what has been learned about product performance since its licensure.

Keywords: Dengue vaccine; Dengvaxia®; efficacy; immunogenicity; safety.

References

    1. Gubler DJ. Dengue, urbanization and globalization: The Unholy Trinity of the 21(st) century. Trop Med Health. 2011;39(4 Suppl):3–11. PubMed PMID: 22500131; PubMed Central PMCID: PMCPMC3317603. doi:10.2149/tmh.2011-S05.
    1. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016;2:16055 PubMed PMID: 27534439. doi:10.1038/nrdp.2016.55.
    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–07. PubMed PMID: 23563266; PubMed Central PMCID: PMCPMC3651993. doi:10.1038/nature12060.
    1. Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, Thaisomboonsuk B, Nisalak A, Weg A, Ellison D, et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature. 2018;557(7707):719–23. 10.1038/s41586-018-0157-4. PubMed PMID: 29795354. doi:10.1038/s41586-018-0157-4.
    1. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A. 2016;113(3):728–33. PubMed PMID: 26729879; PubMed Central PMCID: PMCPMC4725482. doi:10.1073/pnas.1522136113.
    1. Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkhachorn A, Mammen MP, Darunee B, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014;209(3):360–68. PubMed PMID: 23964110; PubMed Central PMCID: PMCPMC3883164. doi:10.1093/infdis/jit436.
    1. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, Kuan G, Gordon A, Balmaseda A, Harris E, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357 PubMed PMID: 23951377; PubMed Central PMCID: PMCPMC3738476. doi:10.1371/journal.pntd.0002357.
    1. Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970;42:350–62.
    1. Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453–65. PubMed PMID: 25230594. doi:10.1016/S0140-6736(14)60572-9.
    1. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science. 1945;101(2634):640–42. PubMed PMID: 17844088. doi:10.1126/science.101.2634.640.
    1. Dengue vaccine: WHO position paper, September 2018 - Recommendations. Vaccine. 2018. PubMed PMID: 30424888. doi:10.1016/j.vaccine.2018.09.063
    1. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73(4):3095–101. PubMed PMID: 10074160; PubMed Central PMCID: PMCPMC104070.
    1. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol. 2000;74(12):5477–85. PubMed PMID: 10823852; PubMed Central PMCID: PMCPMC112032. doi:10.1128/jvi.74.12.5477-5485.2000.
    1. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001;75(16):7290–304. PubMed PMID: 11462001; PubMed Central PMCID: PMCPMC114964. doi:10.1128/JVI.75.16.7290-7304.2001.
    1. Mantel N, Girerd Y, Geny C, Bernard I, Pontvianne J, Lang J, Barban V. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine. 2011;29(38):6629–35. PubMed PMID: 21745519. doi:10.1016/j.vaccine.2011.06.101.
    1. Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG. Structures of immature flavivirus particles. Embo J. 2003;22(11):2604–13. PubMed PMID: 12773377; PubMed Central PMCID: PMCPMC156766. doi:10.1093/emboj/cdg270.
    1. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108(5):717–25. PubMed PMID: 11893341; PubMed Central PMCID: PMCPMC4152842. doi:10.1016/s0092-8674(02)00660-8.
    1. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229–41. PubMed PMID: 21745521. doi:10.1016/j.vaccine.2011.06.094.
    1. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28(3):632–49. PubMed PMID: 19808029. doi:10.1016/j.vaccine.2009.09.098.
    1. Dubayle J, Vialle S, Schneider D, Pontvianne J, Mantel N, Adam O, Guy B, Talaga P. Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur’s tetravalent CYD dengue vaccine. Vaccine. 2015;33(11):1360–68. PubMed PMID: 25660649. doi:10.1016/j.vaccine.2015.01.047.
    1. Deauvieau F, Sanchez V, Balas C, Kennel A, DEM A, Lang J, Guy B. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Am J Trop Med Hyg. 2007;76(1):144–54. PubMed PMID: 17255244.
    1. Higgs S, Vanlandingham DL, Klingler KA, McElroy KL, McGee CE, Harrington L, Lang J, Monath TP, Guirakhoo F. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg. 2006;75(5):986–93. PubMed PMID: 17124001.
    1. Edelman R, Hombach J. “Guidelines for the clinical evaluation of dengue vaccines in endemic areas”: summary of a World Health Organization Technical Consultation. Vaccine. 2008;26(33):4113–19. PubMed PMID: 18597906. doi:10.1016/j.vaccine.2008.05.058.
    1. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, Girakhoo S, Pougatcheva SO, Arroyo J, Trent DW, et al. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004;78(2):1032–38. PubMed PMID: 14694136; PubMed Central PMCID: PMCPMC368746. doi:10.1128/jvi.78.2.1032-1038.2004.
    1. Barban V, Girerd Y, Aguirre M, Gulia S, Pétiard F, Riou P, Barrere B, Lang J. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine. 2007;25(15):2941–50. PubMed PMID: 16914238. doi:10.1016/j.vaccine.2006.06.082.
    1. McGee CE, Tsetsarkin K, Vanlandingham DL, McElroy KL, Lang J, Guy B, Decelle T, Higgs S. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis. 2008;197(5):686–92. PubMed PMID: 18266608; PubMed Central PMCID: PMCPMC2597369. doi:10.1086/527328.
    1. McGee CE, Lewis MG, Claire MS, Wagner W, Lang J, Guy B, Tsetsarkin K, Higgs S, Decelle T. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis. 2008;197(5):693–97. PubMed PMID: 18266603. doi:10.1086/527329.
    1. Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg. 2004;70(1):89–97. PubMed PMID: 14971704. doi:10.4269/ajtmh.2004.70.89.
    1. Monath TP, Myers GA, Beck RA, Knauber M, Scappaticci K, Pullano T, Archambault WT, Catalan J, Miller C, Zhang Z-X, et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals. 2005;33(3):131–44. PubMed PMID: 15975826. doi:10.1016/j.biologicals.2005.03.009.
    1. Ravel G, Mantel N, Silvano J, Rogue A, Guy B, Jackson N, Burdin N. Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey. Vaccine. 2017;35(43):5918–23. PubMed PMID: 28882438. doi:10.1016/j.vaccine.2017.08.071.
    1. Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M, Zhang Z, Lang J, Monath TP, Guirakhoo F. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg. 2005;72(1):74–81. PubMed PMID: 15728870.
    1. Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J, Guy B. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis. 2011;203(1):103–08. PubMed PMID: 21148502; PubMed Central PMCID: PMCPMC3086443. doi:10.1093/infdis/jiq022.
    1. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002;298(1):146–59. PubMed PMID: 12093182. doi:10.1006/viro.2002.1462.
    1. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004;78(9):4761–75. PubMed PMID: 15078958; PubMed Central PMCID: PMCPMC387722. doi:10.1128/jvi.78.9.4761-4775.2004.
    1. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier T-M, Ramirez L, Gregoire V, Charnay C, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg. 2009;80(2):302–11. PubMed PMID: 19190230.
    1. Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, Claude J-B, Lang J. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology. 2012;429(2):91–98. PubMed PMID: 22542002. doi:10.1016/j.virol.2012.03.007.
    1. Barban V, Mantel N, De Montfort A, Pagnon A, Pradezynski F, Lang J, Boudet F. Improvement of the dengue virus (DENV) nonhuman primate model via a reverse translational approach based on dengue vaccine clinical efficacy data against DENV-2 and −4. J Virol. 2018;92(12). PubMed PMID: 29593041; PubMed Central PMCID: PMCPMC5974474. doi:10.1128/JVI.00440-18.
    1. Palucka AK. Dengue virus and dendritic cells. Nat Med. 2000;6(7):748–49. PubMed PMID: 10888920. doi:10.1038/77470.
    1. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9. PubMed PMID: 10608744. doi:10.1086/315215.
    1. Wijeratne DT, Fernando S, Gomes L, Jeewandara C, Ginneliya A, Samarasekara S, Wijewickrama A, Hardman CS, Ogg GS, Malavige GN, et al. Quantification of dengue virus specific T cell responses and correlation with viral load and clinical disease severity in acute dengue infection. PLoS Negl Trop Dis. 2018;12(10):e0006540 PubMed PMID: 30273352; PubMed Central PMCID: PMCPMC6181435. doi:10.1371/journal.pntd.0006540.
    1. Singla M, Kar M, Sethi T, Kabra SK, Lodha R, Chandele A, Medigeshi GR, Williams M. Immune response to dengue virus infection in pediatric patients in New Delhi, India–Association of Viremia, inflammatory mediators and monocytes with disease severity. PLoS Negl Trop Dis. 2016;10(3):e0004497 PubMed PMID: 26982706; PubMed Central PMCID: PMCPMC4794248. doi:10.1371/journal.pntd.0004497.
    1. Pal T, Dutta SK, Mandal S, Saha B, Tripathi A. Differential clinical symptoms among acute phase Indian patients revealed significant association with dengue viral load and serum IFN-gamma level. J Clin Virol. 2014;61(3):365–70. PubMed PMID: 25288310. doi:10.1016/j.jcv.2014.09.003.
    1. Duong V, Ly S, Lorn Try P, Tuiskunen A, Ong S, Chroeung N, Lundkvist A, Leparc-Goffart I, Deubel V, Vong S, et al. Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity. PLoS Negl Trop Dis. 2011;5(7):e1244 PubMed PMID: 21811645; PubMed Central PMCID: PMCPMC3139664. doi:10.1371/journal.pntd.0001244.
    1. Tang Y, Kou Z, Zhang F, Yao X, Liu S, Ma J, Zhou Y, Zhao W, Tang X, Jin X, et al. Both viremia and cytokine levels associate with the lack of severe disease in secondary dengue 1 infection among adult Chinese patients. PLoS One. 2010;5(12):e15631 PubMed PMID: 21206915; PubMed Central PMCID: PMCPMC3012067. doi:10.1371/journal.pone.0015631.
    1. Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, Lin S-C, Ho S-T, Huang J-H, King -C-C. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology. 2003;305(2):330–38. PubMed PMID: 12573578. doi:10.1006/viro.2002.1704.
    1. Fox A, Le NM, Simmons CP, Wolbers M, Wertheim HF, Pham TK, Ninh TTH, Lien TTM, Lien NT, Trung NV, et al. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis. 2011;5(3):e967 PubMed PMID: 21390156; PubMed Central PMCID: PMCPMC3046970. doi:10.1371/journal.pntd.0000967.
    1. Endy TP. Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Front Immunol. 2014;5:183 PubMed PMID: 24795725; PubMed Central PMCID: PMCPMC4006038. doi:10.3389/fimmu.2014.00183.
    1. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004;189(6):990–1000. PubMed PMID: 14999601. doi:10.1086/382280.
    1. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67. PubMed PMID: 22975340. doi:10.1016/S0140-6736(12)61428-7.
    1. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–65. PubMed PMID: 25018116. doi:10.1016/S0140-6736(14)61060-6.
    1. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–23. PubMed PMID: 25365753. doi:10.1056/NEJMoa1411037.
    1. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006;2(2):60–67. PubMed PMID: 17012873. doi:10.4161/hv.2.2.2555.
    1. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201(3):370–77. PubMed PMID: 20059357. doi:10.1086/649916.
    1. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, Wartel A, Crevat D. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29(22):3863–72. PubMed PMID: 21477675. doi:10.1016/j.vaccine.2011.03.057.
    1. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan G. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011;30(1):e9–17. PubMed PMID: 21042231. doi:10.1097/INF.0b013e3181fe05af.
    1. Crevat D, Brion JD, Gailhardou S, Laot TM, Capeding MR. First experience of concomitant vaccination against dengue and MMR in Toddlers. Pediatr Infect Dis J. 2015;34(8):884–92. PubMed PMID: 25966916. doi:10.1097/INF.0000000000000752.
    1. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011;85(4):724–31. PubMed PMID: 21976579; PubMed Central PMCID: PMCPMC3183784. doi:10.4269/ajtmh.2011.10-0436.
    1. Dayan GH, Galan-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother. 2014;10(10):2853–63. PubMed PMID: 25483647; PubMed Central PMCID: PMCPMC5443102. doi:10.4161/21645515.2014.972131.
    1. Dayan GH, Thakur M, Boaz M, Johnson C. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine. 2013;31(44):5047–54. PubMed PMID: 24021313. doi:10.1016/j.vaccine.2013.08.088.
    1. Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013;32(10):1102–09. PubMed PMID: 24067553. doi:10.1097/INF.0b013e31829b8022.
    1. Tran NH, Luong CQ, Vu TQH, Forrat R, Lang J, Vu QD, Bouckenooghe A, Wartel TA. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (Dengvaxia®) in healthy Vietnamese adults and children. J Vaccines Vaccin. 2012;3(7):162.
    1. Tran NH, Chansinghakul D, Chong CY, Low CY, Shek LP, Luong CQ, Fargo C, Wartel TA, Sun S, Skipetrova A, et al, Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. Hum Vaccin Immunother. 2019;1–13. PubMed PMID: 30724660. doi:10.1080/21645515.2019.1578595.
    1. Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, Saville M, Crevat D. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012;30(41):5935–41. PubMed PMID: 22863660. doi:10.1016/j.vaccine.2012.07.043.
    1. Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, Low CY, Oh M-LH, Bouckenooghe A, Wartel TA, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012;8(9):1259–71. PubMed PMID: 22894958; PubMed Central PMCID: PMCPMC3579907. doi:10.4161/hv.21224.
    1. Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, Li Ng J, Yun Toh X, Archuleta S, Wilder-Smith A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9(11):2317–25. PubMed PMID: 23839107; PubMed Central PMCID: PMCPMC3981840. doi:10.4161/hv.25562.
    1. Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM, Giuberti C, Dietze R. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg. 2013;89(6):1058–65. PubMed PMID: 24189367; PubMed Central PMCID: PMCPMC3854882. doi:10.4269/ajtmh.13-0304.
    1. Dubey AP, Agarkhedkar S, Chhatwal J, Narayan A, Ganguly S, Wartel TA, Bouckenooghe A, Menezes J. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. Hum Vaccin Immunother. 2016;12(2):512–18. PubMed PMID: 26291554; PubMed Central PMCID: PMCPMC5049724. doi:10.1080/21645515.2015.1076598.
    1. Kirstein J, Douglas W, Thakur M, Boaz M, Papa T, Skipetrova A, Plennevaux E. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. BMC Infect Dis. 2018;18(1):475 10.1186/s12879-018-3389-x. PubMed PMID: 30241510; PubMed Central PMCID: PMCPMC6150954. doi:10.1186/s12879-018-3109-6.
    1. Coronel D, Garcia-Rivera EJ, Rivera M, Arredondo-Garcia JL, Dietze R, Perroud AP, Cortés M, Bonaparte M, Zhao J, Tila M, et al. Dengue vaccine booster in healthy adolescents and adults in Latin America: Evaluation 4-5 years after a primary 3-dose schedule. Pediatr Infect Dis J. 2019;38(5):e90–e5. PubMed PMID: 30986790. doi:10.1097/INF.0000000000002286.
    1. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–40. PubMed PMID: 29897841. doi:10.1056/NEJMoa1800820.
    1. Arredondo-Garcia JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, Tran NH, Deseda CC, Wirawan DN, Cortés Supelano M, et al. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. 2018;24(7):755–63. PubMed PMID: 29408333. doi:10.1016/j.cmi.2018.01.018.
    1. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HIH, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–206. PubMed PMID: 26214039. doi:10.1056/NEJMoa1506223.
    1. Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, Boaz M, van der Vliet D, Wallace D, Hutagalung Y, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine. 2015;33(39):5127–34. PubMed PMID: 26279339. doi:10.1016/j.vaccine.2015.08.008.
    1. Cortes M, Lopez P, Marquez V, Cortes C, Toro E, Noriega F, Zambrano B. Safety follow-up of a dengue vaccine when administered concomitantly with a yellow fever vaccine in healthy toddlers in Colombia. Pediatr Infect Dis J. 2018;37(11):1190–91. PubMed PMID: 30308599. doi:10.1097/INF.0000000000002172.
    1. Lopez P, Lanata CF, Zambrano B, Cortes M, Andrade T, Amemiya I, Terrones C, Gil AI, Verastegui H, Marquez V, et al. Immunogenicity and safety of yellow fever vaccine (Stamaril) when administered concomitantly with a tetravalent dengue vaccine candidate in healthy toddlers at 12-13 Months of age in Colombia and Peru: a randomized trial. Pediatr Infect Dis J. 2016;35(10):1140–47. PubMed PMID: 27254034. doi:10.1097/INF.0000000000001250.
    1. Hss AS, Koh MT, Tan KK, Chan LG, Zhou L, Bouckenooghe A, Crevat D, Hutagalung Y. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine. 2013;31(49):5814–21. PubMed PMID: 24135573. doi:10.1016/j.vaccine.2013.10.013.
    1. Melo FIR, Morales JJR, De Los Santos AHM, Rivas E, Vigne C, Noriega F. Immunogenicity and safety of a booster injection of DTap-IPV//Hib (Pentaxim) administered concomitantly with tetravalent dengue vaccine in healthy toddlers 15-18 months of age in Mexico: a randomized trial. Pediatr Infect Dis J. 2017;36(6):602–08. PubMed PMID: 28067718. doi:10.1097/INF.0000000000001542.
    1. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003;69(6 Suppl):48–60. PubMed PMID: 14740955. doi:10.4269/ajtmh.2003.69.48.
    1. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng H-S, Tang D, Scherer JM, Hoke CH, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003;69(6 Suppl):24–31. PubMed PMID: 14740952. doi:10.4269/ajtmh.2003.69.6_suppl.0690024.
    1. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin. 2009;5(1):33–40. PubMed PMID: 18670195. doi:10.4161/hv.5.1.6348.
    1. Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33(50):7100–11. PubMed PMID: 26475445. doi:10.1016/j.vaccine.2015.09.108.
    1. Jones JM, Lopez B, Adams L, Galvez FJ, Nunez AS, Santillan NA, Plante L, Hemme RR, Casal M, Hunsperger EA, et al. Binational dengue outbreak along the United States-Mexico Border - Yuma County, Arizona, and Sonora, Mexico, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(19):495–99. PubMed PMID: 27196619. doi:10.15585/mmwr.mm6519a3.
    1. Burattini MN, Lopez LF, Coutinho FA, Siqueira JB Jr., Homsani S, Sarti E, Massad E. Age and regional differences in clinical presentation and risk of hospitalization for dengue in Brazil, 2000-2014. Clinics (Sao Paulo). 2016;71(8):455–63. PubMed PMID: 27626476; PubMed Central PMCID: PMCPMC4975787. doi:10.6061/clinics/2016(08)08.
    1. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC, Videa E, Rodriguez Y, Pérez MA, Cuadra R, et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg. 2005;73(6):1063–70. PubMed PMID: 16354813.
    1. Gamble J, Bethell D, Day NP, Loc PP, Phu NH, Gartside IB, Farrar JF, White NJ. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock?. Clin Sci (Lond). 2000;98(2):211–16. PubMed PMID: 10657278.
    1. Bethell DB, Gamble J, Pham PL, Nguyen MD, Tran TH, Ha TH, Tran TN, Dong TH, Gartside IB, White NJ, et al. Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever. Clin Infect Dis. 2001;32(2):243–53. PubMed PMID: 11170914. doi:10.1086/318453.
    1. Malavige GN, Ogg GS. Pathogenesis of vascular leak in dengue virus infection. Immunology. 2017;151(3):261–69. PubMed PMID: 28437586; PubMed Central PMCID: PMCPMC5461104. doi:10.1111/imm.12748.
    1. Costa VV, Fagundes CT, Souza DG, Teixeira MM. Inflammatory and innate immune responses in dengue infection: protection versus disease induction. Am J Pathol. 2013;182(6):1950–61. PubMed PMID: 23567637. doi:10.1016/j.ajpath.2013.02.027.
    1. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis. 2007;30(5–6):329–40. PubMed PMID: 17645944. doi:10.1016/j.cimid.2007.05.010.
    1. Halstead SB. Dengue. Lancet. 2007;370(9599):1644–52. PubMed PMID: 17993365. doi:10.1016/S0140-6736(07)61687-0.
    1. Clapham H, Cummings DA, Nisalak A, Kalayanarooj S, Thaisomboonsuk B, Klungthong C, Fernandez S, Srikiatkhachorn A, Macareo LR, Lessler J, et al. Epidemiology of infant dengue cases illuminates serotype-specificity in the interaction between immunity and disease, and changes in transmission dynamics. PLoS Negl Trop Dis. 2015;9(12):e0004262 PubMed PMID: 26658730; PubMed Central PMCID: PMCPMC4684242. doi:10.1371/journal.pntd.0004262.
    1. Nascimento EJM, George JK, Velasco M, Bonaparte MI, Zheng L, DiazGranados CA, Marques ETA, Huleatt JW. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018;257:48–57. PubMed PMID: 29567514. doi:10.1016/j.jviromet.2018.03.007.
    1. Olivera-Botello G, Coudeville L, Fanouillere K, Guy B, Chambonneau L, Noriega F, Jackson N. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2-16 years in Asia and Latin America. J Infect Dis. 2016;214(7):994–1000. PubMed PMID: 27418050; PubMed Central PMCID: PMCPMC5021228. doi:10.1093/infdis/jiw297.
    1. Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg. 2003;69(6 Suppl):17–23. PubMed PMID: 14740951. doi:10.4269/ajtmh.2003.69.17.
    1. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol. 2003;77(21):11436–47. PubMed PMID: 14557629; PubMed Central PMCID: PMCPMC229366. doi:10.1128/jvi.77.21.11436-11447.2003.
    1. Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M, Powell TD, Livengood JA, Kinney RM, Huang CY-H, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg. 2011;84(6):978–87. PubMed PMID: 21633037; PubMed Central PMCID: PMCPMC3110349. doi:10.4269/ajtmh.2011.10-0592.
    1. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine. 2000;18 Suppl 2:44–47. PubMed PMID: 10821973. doi:10.1016/s0264-410x(00)00040-2.
    1. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002;66(3):264–72. PubMed PMID: 12139219. doi:10.4269/ajtmh.2002.66.264.
    1. Chanthavanich P, Luxemburger C, Sirivichayakul C, Lapphra K, Pengsaa K, Yoksan S, Sabchareon A, Lang J. Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg. 2006;75(1):26–28. PubMed PMID: 16837703. doi:10.4269/ajtmh.2006.75.1.0750026.
    1. Trent D, Shin J, Hombach J, Knezevic I, Minor P; Group WHOW . WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. Vaccine. 2010;28(52):8246–55. PubMed PMID: 21036129. doi:10.1016/j.vaccine.2010.10.043
    1. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21(2):123–32. 10.1089/vim.2008.0007. PubMed PMID: 18476771.
    1. Thomas SJ. Developing a dengue vaccine: progress and future challenges. Ann N Y Acad Sci. 2014;1323:140–59. PubMed PMID: 24689974. doi:10.1111/nyas.12413.
    1. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis. 2011;24(5):442–50. PubMed PMID: 21799408. doi:10.1097/QCO.0b013e32834a1b0b.
    1. Thomas SJ, Rothman AL. Trials and tribulations on the path to developing a dengue vaccine. Am J Prev Med. 2015;49(6 Suppl 4):S334–44. PubMed PMID: 26590433. doi:10.1016/j.amepre.2015.09.006.
    1. Torresi J, Richmond PC, Heron LG, Qiao M, Marjason J, Starr-Spires L, van der Vliet D, Jin J, Wartel TA, Bouckenooghe A. Replication and excretion of the live attenuated tetravalent dengue Vaccine CYD-TDV in a flavivirus-naive adult population: assessment of vaccine viremia and virus shedding. J Infect Dis. 2017;216(7):834–41. PubMed PMID: 28968794. doi:10.1093/infdis/jix314.
    1. Dorigatti I, Aguas R, Donnelly CA, Guy B, Coudeville L, Jackson N, Saville M, Ferguson NM. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine. 2015;33(31):3746–51. PubMed PMID: 26051515; PubMed Central PMCID: PMCPMC4504002. doi:10.1016/j.vaccine.2015.05.059.
    1. Henein S, Swanstrom J, Byers AM, Moser JM, Shaik SF, Bonaparte M, Jackson N, Guy B, Baric R, de Silva AM. Dissecting antibodies induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in naive and dengue-exposed individuals. J Infect Dis. 2017;215(3):351–58. PubMed PMID: 27932620. doi:10.1093/infdis/jiw576.
    1. Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, Self SG, Chambonneau L, Small R, Jackson N, et al. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J Infect Dis. 2018;217(5):742–53. PubMed PMID: 29194547; PubMed Central PMCID: PMCPMC5854020. doi:10.1093/infdis/jix609.
    1. Lecouturier V, Berry C, Saulnier A, Naville S, Manin C, Girerd-Chambaz Y, Crowe JE, Jackson N, Guy B. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes. Vaccine. 2018. PubMed PMID: 29706291. doi:10.1016/j.vaccine.2018.04.065
    1. Friberg H, Beaumier CM, Park S, Pazoles P, Endy TP, Mathew A, Currier JR, Jarman RG, Anderson KB, Hatch S, et al. Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection. PLoS Negl Trop Dis. 2018;12(12):e0006975 PubMed PMID: 30557313; PubMed Central PMCID: PMCPMC6312351. doi:10.1371/journal.pntd.0006975.
    1. Srikiatkhachorn A, Mathew A, Rothman AL. Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol. 2017;39(5):563–74. 10.1007/s00281-017-0625-1. PubMed PMID: 28401256; PubMed Central PMCID: PMCPMC5496927. doi:10.1007/s00281-017-0625-1.
    1. Rothman AL, Medin CL, Friberg H, Currier JR. Immunopathogenesis versus protection in dengue virus infections. Curr Trop Med Rep. 2014;1(1):13–20. PubMed PMID: 24883262; PubMed Central PMCID: PMCPMC4036645. doi:10.1007/s40475-013-0009-0.
    1. Kurane I, Matsutani T, Suzuki R, Takasaki T, Kalayanarooj S, Green S, Rothman AL, Ennis FA. T-cell responses to dengue virus in humans. Trop Med Health. 2011;39(4 Suppl):45–51. PubMed PMID: 22500136; PubMed Central PMCID: PMCPMC3317604. doi:10.2149/tmh.2011-S09.
    1. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532–43. PubMed PMID: 21760609. doi:10.1038/nri3014.
    1. Friberg H, Burns L, Woda M, Kalayanarooj S, Endy TP, Stephens HAF, Green S, Rothman AL, Mathew A. Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol. 2011;89(1):122–29. PubMed PMID: 20421879; PubMed Central PMCID: PMCPMC2929403. doi:10.1038/icb.2010.61.
    1. Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol. 2010;338:83–98. PubMed PMID: 19802580. doi:10.1007/978-3-642-02215-9_7.
    1. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26(45):5712–21. PubMed PMID: 18762226. doi:10.1016/j.vaccine.2008.08.019.
    1. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016;14(1):45–54. PubMed PMID: 26639777. doi:10.1038/nrmicro.2015.2.
    1. Anderson KB, Endy TP, Thomas SJ. The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy. Lancet Infect Dis. 2018;18(10):e333–e8. PubMed PMID: 29784457. doi:10.1016/S1473-3099(18)30126-9.
    1. Oktarianti R, Senjarini K, Hayano T, Fatchiyah F. Proteomic analysis of immunogenic proteins from salivary glands of Aedes aegypti. J Infect Public Health. 2015;8(6):575–82. PubMed PMID: 26054892. doi:10.1016/j.jiph.2015.04.022.
    1. Doucoure S, Mouchet F, Cornelie S, Drame PM, D’Ortenzio E, DeHecq JS, Remoue F. Human antibody response to Aedes albopictus salivary proteins: a potential biomarker to evaluate the efficacy of vector control in an area of Chikungunya and Dengue virus transmission. Biomed Res Int. 2014;2014:746509 PubMed PMID: 24822216; PubMed Central PMCID: PMCPMC4005104. doi:10.1155/2014/746509.
    1. Machain-Williams C, Mammen MP Jr., Zeidner NS, Beaty BJ, Prenni JE, Nisalak A, Blair CD. Association of human immune response to Aedes aegypti salivary proteins with dengue disease severity. Parasite Immunol. 2012;34(1):15–22. PubMed PMID: 21995849; PubMed Central PMCID: PMCPMC3240707. doi:10.1111/j.1365-3024.2011.01339.x.
    1. Velumani S, Toh YX, Balasingam S, Archuleta S, Leo YS, Gan VC, Thein TL, Wilder-Smith A, Fink K. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees. Hum Vaccin Immunother. 2016;12(5):1265–73. PubMed PMID: 26889737; PubMed Central PMCID: PMCPMC4963049. doi:10.1080/21645515.2015.1126012.
    1. Vigne C, Dupuy M, Richetin A, Guy B, Jackson N, Bonaparte M, Hu B, Saville M, Chansinghakul D, Noriega F, et al. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination. Hum Vaccin Immunother. 2017;1–13. PubMed PMID: 28598256. doi:10.1080/21645515.2017.1333211
    1. Rabaa MA, Girerd-Chambaz Y, Duong Thi Hue K, Vu Tuan T, Wills B, Bonaparte M, van der Vliet D, Langevin E, Cortes M, Zambrano B, et al. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy. Elife. 2017;6 PubMed PMID: 28871961; PubMed Central PMCID: PMCPMC5584992. doi:10.7554/eLife.24196.
    1. Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, Girerd-Chambaz Y, Langevin E, Frago C, Guy B, et al. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proc Natl Acad Sci U S A. 2018;115(36):E8378–E87. PubMed PMID: 30127007; PubMed Central PMCID: PMCPMC6130398. doi:10.1073/pnas.1714250115.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다